Results 51 to 60 of about 18,961 (179)

Aleukemic Leukemia Cutis Manifesting with Disseminated Nodular Eruptions and a Plaque Preceding Acute Monocytic Leukemia: A Case Report

open access: yesCase Reports in Oncology, 2011
Aleukemic leukemia cutis (ALC), a discrete tumor of leukemic cells involving the skin, may be the first manifestation of acute myeloid leukemia, preceding the onset in marrow and blood by months and years.
Ipek Yonal   +4 more
doaj   +1 more source

A case of rhinocerebral mucormycosis with brain abscess drained by endoscopic endonasal skull base surgery

open access: yesMedical Mycology Case Reports, 2020
A 70-year-old Japanese man undergoing remission induction therapy for acute monocytic leukemia (AML-M5b) developed fever and headache, and was started on antibiotics and liposomal amphotericin B (L-AMB).
Kensuke Uraguchi   +9 more
doaj   +1 more source

Development of a Novel Polyleucine‐Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus

open access: yesSmall, EarlyView.
Self‐assembling amphiphilic peptide L15K6 is used as a novel immunoadjuvant for the development of a Group A Streptococcus vaccine. Robust antigen‐specific IgG responses are generated and manage to kill isolated strains of Group A Streptococcus. Cellular and bulk RNA sequencing data reveals that L15K6 regulates immune responses potentially through TLR ...
Lantian Lu   +25 more
wiley   +1 more source

TRANSFORMATION OF CHRONIC MYELOMONOCYTIC LEUKEMIA TO ACUTE MONOCYTIC LEUKEMIA IN AN ELDERLY PATIENT: A CASE REPORT

open access: yesHematology, Transfusion and Cell Therapy
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder that exhibits both myelodysplastic and myeloproliferative features. Progression to acute monocytic leukemia is a notable complication, especially in elderly patients.
AM Oba   +6 more
doaj   +1 more source

The effects of photodynamic therapy on leukemia cells mediated by KillerRed, a genetically encoded fluorescent protein photosensitizer

open access: yesBMC Cancer, 2019
Background Leukemia is a cancer of blood and bone marrow cells, causing about 300,000 deaths worldwide. Photodynamic therapy (PDT) is a promising alternative for the treatment of malignant tumors.
Meng Yuan   +6 more
doaj   +1 more source

Securinine, a myeloid differentiation agent with therapeutic potential for AML. [PDF]

open access: yesPLoS ONE, 2011
As the defining feature of Acute Myeloid Leukemia (AML) is a maturation arrest, a highly desirable therapeutic strategy is to induce leukemic cell maturation. This therapeutic strategy has the potential of avoiding the significant side effects that occur
Kalpana Gupta   +8 more
doaj   +1 more source

Acute Monocytic Leukaemia with Cutaneous Manifestation

open access: yesJournal of Cutaneous Pathology, 2005
A 50‐year‐old Caucasian male presented with generalised skin rash. Gingival hyperplasia and hepatosplenomegaly were also noted. His laboratory data showed hemoglobin of 10.3 g/dL, white blood cell count of 203.6 K/uL and platelet count of 72 K/uL. Peripheral blood smears revealed that 67% of the white blood cells was monoblasts, 25% was promonocytes ...
Leilei, Chen   +3 more
openaire   +2 more sources

Solamargine induces acute myeloid leukemia differentiation through TLR8 activation

open access: yesVIEW, EarlyView.
SM, a steroidal alkaloid from Solanum nigrum L. has shown anticancer effect on various kinds of human cancer cells, yet its effect on leukemia cells remains unclear. This study examines antileukemic activities of SM in AML cells. Results indicate SM inhibits growth and promotes apoptosis of AML cells.
Qiaoyan Han   +11 more
wiley   +1 more source

B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phenotype acute leukemia with additional chromosomal aberrations in the course of therapy

open access: yesHematology Reports, 2012
About 5% of adult B-cell acute lymphoblastic leukemias (B-ALL) are characterized by t(4;11)(q21;q23), which confers peculiar features to this B-ALL subtype, including a very immature immunophenotype and poor prognosis.
Giovanni Carulli   +8 more
doaj   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy